Solid Biosciences is trading 8.6% up at $9.30 amid continued investor response to its August 6 earnings release, including a smaller-than-expected loss and generally well-tolerated SGT-003 treatment in 53 participants.
- August 10, Citizens reiterated its Market Outperform rating with a $15 price target, citing progress toward greater Duchenne-program clarity.
- The broader market was slightly weaker; company-specific catalysts appear dominant.
- No separate August 11 announcement was identified; pre-market volume/activity data were unavailable, leaving liquidity and durability uncertain.